{"id":46139,"date":"2025-11-08T14:27:36","date_gmt":"2025-11-08T06:27:36","guid":{"rendered":"https:\/\/flcube.com\/?p=46139"},"modified":"2025-11-08T14:27:38","modified_gmt":"2025-11-08T06:27:38","slug":"us-fdas-cnpv-fast%e2%80%91track-program-expands-to-15-drugs-cutting-review-time-to-months","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=46139","title":{"rendered":"US FDA\u2019s CNPV Fast\u2011Track Program Expands to 15 Drugs, Cutting Review Time to Months"},"content":{"rendered":"\n<p>The <strong>Commissioner\u2019s National Priority Voucher (CNPV)<\/strong> pilot has just added <strong>15 therapies<\/strong> to its two\u2011batch rollout, offering manufacturers an accelerated route to approval. The first tranche of nine drugs, including infertility and cancer treatments, and a second tranche of six\u2014spanning oncology, infectious disease, and metabolic disorders\u2014signal a broadened FDA commitment to faster access for priority products.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-program-overview\">Program Overview<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>What is CNPV?<\/strong><\/li>\n\n\n\n<li>A voluntary program that reserves a \u201cvoucher\u201d for a single application, guaranteeing a single\u2011file review and a decision within <strong>a few months<\/strong> instead of the typical 10\u2011plus\u2011month cycle.<\/li>\n\n\n\n<li><strong>Eligibility<\/strong><\/li>\n\n\n\n<li>Submissions that address national medical priorities (rare disease, oncology, drug\u2011resistance, etc.) and meet pre\u2011defined scientific rigor.<\/li>\n\n\n\n<li><strong>Benefits<\/strong><\/li>\n\n\n\n<li><strong>Rapid decision<\/strong>\u2014provided the application is complete.<\/li>\n\n\n\n<li><strong>Time\u2011and\u2011cost savings<\/strong> for companies that would otherwise face long IND and NDA stages.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-first-batch-9-drugs\">First Batch \u2013 9 Drugs<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>#<\/th><th>Drug<\/th><th>Indication<\/th><\/tr><\/thead><tbody><tr><td>1<\/td><td><strong>Pergoveris<\/strong><\/td><td>Infertility<\/td><\/tr><tr><td>2<\/td><td><strong>Teplizumab<\/strong><\/td><td>Type\u202fI diabetes<\/td><\/tr><tr><td>3<\/td><td><strong>Cytisinicline<\/strong><\/td><td>Nicotine vaping addiction<\/td><\/tr><tr><td>4<\/td><td><strong>DB\u2011OTO<\/strong><\/td><td>Deafness<\/td><\/tr><tr><td>5<\/td><td><strong>Cenegermin\u2011bkbj<\/strong><\/td><td>Blindness<\/td><\/tr><tr><td>6<\/td><td><strong>RMC\u20116236<\/strong><\/td><td>Pancreatic cancer<\/td><\/tr><tr><td>7<\/td><td><strong>Bitopertin<\/strong><\/td><td>Porphyria<\/td><\/tr><tr><td>8<\/td><td><strong>Ketamine<\/strong><\/td><td>Domestic production of a critical drug for general anaesthesia<\/td><\/tr><tr><td>9<\/td><td><strong>Augmentin\u202fXR<\/strong><\/td><td>Domestic production of a common antibiotic<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-second-batch-6-drugs\">Second Batch \u2013 6 Drugs<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>#<\/th><th>Drug<\/th><th>Indication<\/th><\/tr><\/thead><tbody><tr><td>1<\/td><td><strong>Zongertinib<\/strong><\/td><td>HER2\u2011positive lung cancer<\/td><\/tr><tr><td>2<\/td><td><strong>Bedaquiline<\/strong><\/td><td>Drug\u2011resistant tuberculosis in children<\/td><\/tr><tr><td>3<\/td><td><strong>Dostarlimab<\/strong><\/td><td>Rectal cancer<\/td><\/tr><tr><td>4<\/td><td><strong>Casgevy<\/strong><\/td><td>Sickle cell disease<\/td><\/tr><tr><td>5<\/td><td><strong>Orforglipron<\/strong><\/td><td>Obesity &amp; related conditions<\/td><\/tr><tr><td>6<\/td><td><strong>Wegovy<\/strong><\/td><td>Obesity &amp; related conditions<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-implications-for-the-u-s-bio-pharma-landscape\">Implications for the U.S. Bio\u2011pharma Landscape<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Speedy Innovation Cycle<\/strong> \u2013 The CNPV program could shrink the median drug\u2011approval window by half, creating a competitive edge for U.S. developers.<\/li>\n\n\n\n<li><strong>Market Access<\/strong> \u2013 Companies that secure a voucher may enter the U.S. market faster, capturing early\u2011payer contracts and first\u2011mover advantage.<\/li>\n\n\n\n<li><strong>Risk Management<\/strong> \u2013 FDA staff retain the right to extend reviews \u201cas necessary,\u201d underscoring that voucher holders must submit <strong>comprehensive data packages<\/strong> to avoid surprises.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>The Commissioner\u2019s National Priority Voucher (CNPV) pilot has just added 15 therapies to its two\u2011batch&#8230;<\/p>\n","protected":false},"author":1,"featured_media":46140,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[4],"tags":[80],"class_list":["post-46139","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-policy-regulatory","tag-priority-reviews"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>US FDA\u2019s CNPV Fast\u2011Track Program Expands to 15 Drugs, Cutting Review Time to Months - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"The Commissioner\u2019s National Priority Voucher (CNPV) pilot has just added 15 therapies to its two\u2011batch rollout, offering manufacturers an accelerated route to approval. The first tranche of nine drugs, including infertility and cancer treatments, and a second tranche of six\u2014spanning oncology, infectious disease, and metabolic disorders\u2014signal a broadened FDA commitment to faster access for priority products.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=46139\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"US FDA\u2019s CNPV Fast\u2011Track Program Expands to 15 Drugs, Cutting Review Time to Months\" \/>\n<meta property=\"og:description\" content=\"The Commissioner\u2019s National Priority Voucher (CNPV) pilot has just added 15 therapies to its two\u2011batch rollout, offering manufacturers an accelerated route to approval. The first tranche of nine drugs, including infertility and cancer treatments, and a second tranche of six\u2014spanning oncology, infectious disease, and metabolic disorders\u2014signal a broadened FDA commitment to faster access for priority products.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=46139\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-08T06:27:36+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-08T06:27:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0803-1.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46139#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46139\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"US FDA\u2019s CNPV Fast\u2011Track Program Expands to 15 Drugs, Cutting Review Time to Months\",\"datePublished\":\"2025-11-08T06:27:36+00:00\",\"dateModified\":\"2025-11-08T06:27:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46139\"},\"wordCount\":309,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46139#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/0803-1.webp\",\"keywords\":[\"Priority reviews\"],\"articleSection\":[\"Policy \\\/ Regulatory\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=46139#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46139\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=46139\",\"name\":\"US FDA\u2019s CNPV Fast\u2011Track Program Expands to 15 Drugs, Cutting Review Time to Months - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46139#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46139#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/0803-1.webp\",\"datePublished\":\"2025-11-08T06:27:36+00:00\",\"dateModified\":\"2025-11-08T06:27:38+00:00\",\"description\":\"The Commissioner\u2019s National Priority Voucher (CNPV) pilot has just added 15 therapies to its two\u2011batch rollout, offering manufacturers an accelerated route to approval. The first tranche of nine drugs, including infertility and cancer treatments, and a second tranche of six\u2014spanning oncology, infectious disease, and metabolic disorders\u2014signal a broadened FDA commitment to faster access for priority products.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46139#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=46139\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46139#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/0803-1.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/0803-1.webp\",\"width\":1080,\"height\":608,\"caption\":\"US FDA\u2019s CNPV Fast\u2011Track Program Expands to 15 Drugs, Cutting Review Time to Months\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46139#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"US FDA\u2019s CNPV Fast\u2011Track Program Expands to 15 Drugs, Cutting Review Time to Months\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"US FDA\u2019s CNPV Fast\u2011Track Program Expands to 15 Drugs, Cutting Review Time to Months - Insight, China&#039;s Pharmaceutical Industry","description":"The Commissioner\u2019s National Priority Voucher (CNPV) pilot has just added 15 therapies to its two\u2011batch rollout, offering manufacturers an accelerated route to approval. The first tranche of nine drugs, including infertility and cancer treatments, and a second tranche of six\u2014spanning oncology, infectious disease, and metabolic disorders\u2014signal a broadened FDA commitment to faster access for priority products.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=46139","og_locale":"en_US","og_type":"article","og_title":"US FDA\u2019s CNPV Fast\u2011Track Program Expands to 15 Drugs, Cutting Review Time to Months","og_description":"The Commissioner\u2019s National Priority Voucher (CNPV) pilot has just added 15 therapies to its two\u2011batch rollout, offering manufacturers an accelerated route to approval. The first tranche of nine drugs, including infertility and cancer treatments, and a second tranche of six\u2014spanning oncology, infectious disease, and metabolic disorders\u2014signal a broadened FDA commitment to faster access for priority products.","og_url":"https:\/\/flcube.com\/?p=46139","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-11-08T06:27:36+00:00","article_modified_time":"2025-11-08T06:27:38+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0803-1.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=46139#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=46139"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"US FDA\u2019s CNPV Fast\u2011Track Program Expands to 15 Drugs, Cutting Review Time to Months","datePublished":"2025-11-08T06:27:36+00:00","dateModified":"2025-11-08T06:27:38+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=46139"},"wordCount":309,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=46139#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0803-1.webp","keywords":["Priority reviews"],"articleSection":["Policy \/ Regulatory"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=46139#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=46139","url":"https:\/\/flcube.com\/?p=46139","name":"US FDA\u2019s CNPV Fast\u2011Track Program Expands to 15 Drugs, Cutting Review Time to Months - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=46139#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=46139#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0803-1.webp","datePublished":"2025-11-08T06:27:36+00:00","dateModified":"2025-11-08T06:27:38+00:00","description":"The Commissioner\u2019s National Priority Voucher (CNPV) pilot has just added 15 therapies to its two\u2011batch rollout, offering manufacturers an accelerated route to approval. The first tranche of nine drugs, including infertility and cancer treatments, and a second tranche of six\u2014spanning oncology, infectious disease, and metabolic disorders\u2014signal a broadened FDA commitment to faster access for priority products.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=46139#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=46139"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=46139#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0803-1.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0803-1.webp","width":1080,"height":608,"caption":"US FDA\u2019s CNPV Fast\u2011Track Program Expands to 15 Drugs, Cutting Review Time to Months"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=46139#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"US FDA\u2019s CNPV Fast\u2011Track Program Expands to 15 Drugs, Cutting Review Time to Months"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0803-1.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/46139","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=46139"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/46139\/revisions"}],"predecessor-version":[{"id":46141,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/46139\/revisions\/46141"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/46140"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=46139"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=46139"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=46139"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}